Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...
AstraZeneca (AZN) Gets a Hold from Jefferies
In a report released today, Peter Welford from Jefferies maintained a Hold rating on AstraZeneca (AZN – Research Report), with a price target ...
GSK Tech Ecosystem Profile - Digital Transformation Strategies and Innovation Programs
The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) ...
GSK rises Wednesday, outperforms market
GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.
AstraZeneca reports strong results boosted by promising trials
AstraZeneca continued to see strong growth in 2024 on the back of a series of positive trials, as well as a solid pipeline of products.
GSK launches $2.5 billion buyback, lifts sales target after stellar Q4
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
AstraZeneca shareholders say they need clarity on China investigations
AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...